PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000850132.55221.5c |
| _version_ | 1827336362924179456 |
|---|---|
| author | N. Daver M. Maris R. Ramchandren D. Bixby K. Doucette R. Mawad D. Egan D. Stevens J. Zonder N. Molloy A. Scheuber I. Bruns I. Mantzaris M. Konopleva A. D. Goldberg |
| author_facet | N. Daver M. Maris R. Ramchandren D. Bixby K. Doucette R. Mawad D. Egan D. Stevens J. Zonder N. Molloy A. Scheuber I. Bruns I. Mantzaris M. Konopleva A. D. Goldberg |
| author_sort | N. Daver |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:29:23Z |
| format | Article |
| id | doaj.art-d285e1acccc14cdd875900675d68e8aa |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:29:23Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-d285e1acccc14cdd875900675d68e8aa2024-03-02T06:40:54ZengWileyHemaSphere2572-92412022-06-0161700170110.1097/01.HS9.0000850132.55221.5c202206003-01700PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AMLN. Daver0M. Maris1R. Ramchandren2D. Bixby3K. Doucette4R. Mawad5D. Egan6D. Stevens7J. Zonder8N. Molloy9A. Scheuber10I. Bruns11I. Mantzaris12M. Konopleva13A. D. Goldberg141 University of Texas MD Anderson Cancer Center, Houston2 Colorado Blood Cancer Institute and Sarah Cannon Research Institute, Denver3 University of Tennessee, Knoxville4 University of Michigan, Ann Arbor5 Georgetown University Hospital, Washington, DC6 Swedish Cancer Institute, Seattle6 Swedish Cancer Institute, Seattle7 Norton Healthcare, Louisville8 Karmanos Cancer Institute/Wayne State University, Detroit9 Trillium Therapeutics, a Pfizer company’, Cambridge9 Trillium Therapeutics, a Pfizer company’, Cambridge9 Trillium Therapeutics, a Pfizer company’, Cambridge10 Einstein College of Medicine1 University of Texas MD Anderson Cancer Center, Houston11 Memorial Sloan Kettering, New York, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000850132.55221.5c |
| spellingShingle | N. Daver M. Maris R. Ramchandren D. Bixby K. Doucette R. Mawad D. Egan D. Stevens J. Zonder N. Molloy A. Scheuber I. Bruns I. Mantzaris M. Konopleva A. D. Goldberg PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML HemaSphere |
| title | PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML |
| title_full | PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML |
| title_fullStr | PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML |
| title_full_unstemmed | PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML |
| title_short | PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML |
| title_sort | pb1820 cd47 blocker tti 622 combined with azacitidine in patients with tp53 mutated acute myeloid leukemia aml and with azacitidine venetoclax in elderly or unfit patients with tp53 wildtype aml |
| url | http://journals.lww.com/10.1097/01.HS9.0000850132.55221.5c |
| work_keys_str_mv | AT ndaver pb1820cd47blockertti622combinedwithazacitidineinpatientswithtp53mutatedacutemyeloidleukemiaamlandwithazacitidinevenetoclaxinelderlyorunfitpatientswithtp53wildtypeaml AT mmaris pb1820cd47blockertti622combinedwithazacitidineinpatientswithtp53mutatedacutemyeloidleukemiaamlandwithazacitidinevenetoclaxinelderlyorunfitpatientswithtp53wildtypeaml AT rramchandren pb1820cd47blockertti622combinedwithazacitidineinpatientswithtp53mutatedacutemyeloidleukemiaamlandwithazacitidinevenetoclaxinelderlyorunfitpatientswithtp53wildtypeaml AT dbixby pb1820cd47blockertti622combinedwithazacitidineinpatientswithtp53mutatedacutemyeloidleukemiaamlandwithazacitidinevenetoclaxinelderlyorunfitpatientswithtp53wildtypeaml AT kdoucette pb1820cd47blockertti622combinedwithazacitidineinpatientswithtp53mutatedacutemyeloidleukemiaamlandwithazacitidinevenetoclaxinelderlyorunfitpatientswithtp53wildtypeaml AT rmawad pb1820cd47blockertti622combinedwithazacitidineinpatientswithtp53mutatedacutemyeloidleukemiaamlandwithazacitidinevenetoclaxinelderlyorunfitpatientswithtp53wildtypeaml AT degan pb1820cd47blockertti622combinedwithazacitidineinpatientswithtp53mutatedacutemyeloidleukemiaamlandwithazacitidinevenetoclaxinelderlyorunfitpatientswithtp53wildtypeaml AT dstevens pb1820cd47blockertti622combinedwithazacitidineinpatientswithtp53mutatedacutemyeloidleukemiaamlandwithazacitidinevenetoclaxinelderlyorunfitpatientswithtp53wildtypeaml AT jzonder pb1820cd47blockertti622combinedwithazacitidineinpatientswithtp53mutatedacutemyeloidleukemiaamlandwithazacitidinevenetoclaxinelderlyorunfitpatientswithtp53wildtypeaml AT nmolloy pb1820cd47blockertti622combinedwithazacitidineinpatientswithtp53mutatedacutemyeloidleukemiaamlandwithazacitidinevenetoclaxinelderlyorunfitpatientswithtp53wildtypeaml AT ascheuber pb1820cd47blockertti622combinedwithazacitidineinpatientswithtp53mutatedacutemyeloidleukemiaamlandwithazacitidinevenetoclaxinelderlyorunfitpatientswithtp53wildtypeaml AT ibruns pb1820cd47blockertti622combinedwithazacitidineinpatientswithtp53mutatedacutemyeloidleukemiaamlandwithazacitidinevenetoclaxinelderlyorunfitpatientswithtp53wildtypeaml AT imantzaris pb1820cd47blockertti622combinedwithazacitidineinpatientswithtp53mutatedacutemyeloidleukemiaamlandwithazacitidinevenetoclaxinelderlyorunfitpatientswithtp53wildtypeaml AT mkonopleva pb1820cd47blockertti622combinedwithazacitidineinpatientswithtp53mutatedacutemyeloidleukemiaamlandwithazacitidinevenetoclaxinelderlyorunfitpatientswithtp53wildtypeaml AT adgoldberg pb1820cd47blockertti622combinedwithazacitidineinpatientswithtp53mutatedacutemyeloidleukemiaamlandwithazacitidinevenetoclaxinelderlyorunfitpatientswithtp53wildtypeaml |